Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

News SummaryMost relevantAll newsSector news 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
07/12/2011 | 10:20am CEST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)


Date of Board of Directors resolution: June 27, 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
09/27 DAIICHI SANKYO : Initiates Phase 3 study of CS-3150, a Novel Mineralocorticoid R..
09/16 DAIICHI SANKYO : Selected for Dow Jones Sustainability Asia Pacific Indices for ..
09/15 DAIICHI SANKYO : Reports from Daiichi Sankyo Add New Data to Findings in Thrombo..
09/15 DAIICHI SANKYO : Researchers at Daiichi Sankyo Target Amphibian Venoms [Synthesi..
09/14 DAIICHI SANKYO : Selected for Dow Jones Sustainability Asia Pacific Indices for ..
09/09 DAIICHI SANKYO : New Findings on Carboxylic Ester Hydrolases from Daiichi Sankyo..
09/09 DAIICHI SANKYO : Galderma and Daiichi Sankyo, Inc. Pledge Support as Silver Spon..
09/01 VEEVA : Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and ..
09/01 DAIICHI SANKYO : Announces Status Relating to Acquisition of Own Shares
08/31 DAIICHI SANKYO : ENSURE-AF Data Support the Efficacy and Safety Profile of Daiic..
More news
Sector news : Pharmaceuticals - NEC
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Daiichi Sankyo launches Phase 3 clinical trial of CS-3150 in Japanese patient..
09/16 Is This The Next Valeant?
08/18 FDA rejects Portola's AndexXa NDA; shares down 18% premarket
07/15 Therapy Focus - Another Try For FGFR Inhibitors
07/14 Amgen and Daiichi Sankyo team up to market biosimilars in Japan
Financials ( JPY)
Sales 2017 920 730 M
EBIT 2017 -
Net income 2017 69 446 M
Finance 2017 310 176 M
Yield 2017 2,86%
P/E ratio 2017 23,64
P/E ratio 2018 24,69
EV / Sales 2017 1,55x
EV / Sales 2018 1,60x
Capitalization 1 736 723 M
More Financials
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 12
Average target price 2 455  JPY
Spread / Average Target 0,22%
Consensus details
EPS Revisions
More Estimates Revisions
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura Vice President-Finance & Accounting Department
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results